{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:25:37Z","timestamp":1789644337195,"version":"4.0.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clindermatol.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T06:29:14Z","timestamp":1523514554000},"page":"508-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis"],"prefix":"10.1016","volume":"36","author":[{"given":"Danielle M.","family":"Tartar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2018.04.008_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0760","article-title":"Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis","volume":"4","author":"Suber","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002281-200011000-00001","article-title":"Update on myositis-specific and myositis-associated autoantibodies","volume":"12","author":"Targoff","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMp038142","article-title":"Autoantibodies in systemic lupus erythematosus\u2014there before you know it","volume":"349","author":"Shmerling","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrrheum.2016.23","article-title":"DNA-damaging autoantibodies and cancer: the lupus butterfly theory","volume":"12","author":"Noble","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1191\/096120301669579565","article-title":"Antinuclear antibodies: to penetrate or not to penetrate, that was the question","volume":"10","author":"Alarc\u00f3n-Segovia","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0035","doi-asserted-by":"crossref","first-page":"19269","DOI":"10.1074\/jbc.C114.571026","article-title":"Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis","volume":"289","author":"Zhou","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-065X.1999.tb01310.x","article-title":"The central and multiple roles of B cells in lupus pathogenesis","volume":"169","author":"Chan","year":"1999","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0045","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.autrev.2016.07.009","article-title":"The role of B cells and autoantibodies in neuropsychiatric lupus","volume":"15","author":"Wen","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0165-5728(01)00412-X","article-title":"Immunoglobulin binding to brain in autoimmune mice","volume":"120","author":"Zameer","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0019-5154.100486","article-title":"Clinical presentation and evaluation of dermatomyositis","volume":"57","author":"Marvi","year":"2012","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archdermatol.2011.41","article-title":"Dermatomyositis autoantibodies: clinical markers of patients past, present, and future","volume":"147","author":"Fiorentino","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cyto.2014.10.012","article-title":"Interferons as components of the complex web of reactions sustaining inflammation in idiopathic inflammatory myopathies","volume":"74","author":"De Paepe","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0085","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0090","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bjd.15468","article-title":"A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-\u03b3","volume":"177","author":"Meisterfeld","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0095","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.33402","article-title":"Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection","volume":"64","author":"Fiorentino","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5114\/reum.2016.58756","article-title":"Clinical characteristics of patients with anti-TIF1-\u03b3 antibodies","volume":"54","author":"Masiak","year":"2016","journal-title":"Reumatologia"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","article-title":"Expression of the dermatomyositis autoantigen transcription intermediary factor 1\u03b3 in regenerating muscle","volume":"67","author":"Mohassel","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0135","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.24702","article-title":"Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women","volume":"60","author":"Love","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0145","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0150","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1600-0781.2004.00115.x","article-title":"Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects","volume":"20","author":"Dourmishev","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0160","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0165","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2013.10416","article-title":"Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis","volume":"150","author":"Valenzuela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0170","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1091\/mbc.e06-08-0747","article-title":"Dynamic regulation of p53 subnuclear localization and senescence by MORC3","volume":"18","author":"Takahashi","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0175","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0185","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0190","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, andincreased malignancy risk","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0195","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0200","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4817275","article-title":"NXP-2 positive dermatomyositis: a unique clinical presentation","author":"Butt","year":"2017","journal-title":"Case Rep Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.clindermatol.2018.04.008_bb0215","article-title":"Subcutaneous edema, distal weakness and dysphagia associated with the NXP2 antibody [abstract]","volume":"67","author":"Albayda","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"Mugii","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0230","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MD.0b013e3182606f0b","article-title":"A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature","volume":"91","author":"Chaisson","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0235","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0240","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0245","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0250","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0255","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/atm.2017.03.94","article-title":"MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis","volume":"5","author":"Sontheimer","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0265","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0270","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.13112","article-title":"Spontaneous pneumomediastinum in a dermatomyositis patient with antimelanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant","author":"Chan","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0275","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.14801","article-title":"Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis","volume":"176","author":"Ang","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12948-015-0031-y","article-title":"MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations","volume":"13","author":"Parronchi","year":"2015","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.reuma.2016.10.010","article-title":"Anti-MDA5 dermatomyositis mimicking psoriatic arthritis","author":"Cabezas-Rodr\u00edguez","year":"2016","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0290","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0295","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s11606-016-3769-0","article-title":"Anti-MDA5-Positive dermatomyositis presenting as fever of unknown origin","volume":"31","author":"Lee","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0305","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0310","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0315","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0320","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0325","doi-asserted-by":"crossref","first-page":"34976","DOI":"10.1074\/jbc.M805383200","article-title":"UV radiation regulates Mi-2 through protein translation and stability","volume":"283","author":"Burd","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0330","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0335","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0345","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2017.01.008","article-title":"Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study","volume":"16","author":"Bartoloni","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0355","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","article-title":"Role of Jo-1 in the Immunopathogenesis of the anti-synthetase syndrome","volume":"17","author":"Ascherman","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0360","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0370","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-016-1704-1","article-title":"Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets","volume":"309","author":"Merlo","year":"2017","journal-title":"Archives Dermatological Res"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"AutoI Immun Highlights"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0380","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0385","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00296-017-3718-1","article-title":"A review of the role and clinical utility of anti-Ro52\/TRIM21 in systemic autoimmunity","volume":"37","author":"Lee","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0390","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0395","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0400","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0405","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0410","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0415","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0420","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0425","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/0961203302lu186oa","article-title":"SLE\/myositis overlap: are the manifestations of SLE different in overlap disease?","volume":"11","author":"Dayal","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0430","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/BOR.0000000000000325","article-title":"Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis","volume":"28","author":"Choi","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0435","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.autrev.2015.07.012","article-title":"Quality of life in systemic sclerosis","volume":"14","author":"Almeida","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0440","series-title":"Dermatology","author":"Bolognia","year":"2012"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0445","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0455","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0460","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0465","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-015-0513-5","article-title":"Functional autoantibodies in systemic sclerosis","volume":"37","author":"G\u00fcnther","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0470","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0475","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jcp.10065","article-title":"Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF-beta1","volume":"191","author":"Falanga","year":"2002","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0480","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G","article-title":"Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients","volume":"43","author":"Poormoghim","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0485","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0490","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0495","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0500","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1046\/j.1365-2249.2002.01991.x","article-title":"Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations","volume":"130","author":"Van Eenennaam","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0505","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1529-0131(199801)41:1<74::AID-ART10>3.0.CO;2-C","article-title":"HLA and clinical associations in systemic sclerosis patients with anti-Th\/To antibodies","volume":"41","author":"Falkner","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0510","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-Th\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0515","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/1756-185X.13019","article-title":"Anti-PM\/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature","volume":"20","author":"Kohara","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0520","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients","volume":"66","author":"D\u2019Aoust","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0525","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0530","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0535","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/ dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0540","first-page":"S12","article-title":"Anti-PM-Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0550","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0555","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.39558","article-title":"Anti-interferon-inducible protein 16 antibodies associate with digital gangrene in patients with scleroderma","volume":"68","author":"McMahan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0560","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molimm.2011.11.004","article-title":"Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization","volume":"49","author":"Veeranki","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0565","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1196\/annals.1423.006","article-title":"Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders","volume":"1110","author":"Mondini","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0570","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/art.22266","article-title":"A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16","volume":"54","author":"Mondini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0575","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/art.24586","article-title":"Anti-U11\/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis","volume":"61","author":"Fertig","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0580","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0585","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0590","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0595","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","article-title":"Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis","volume":"43","author":"Kuwana","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0600","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0605","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0610","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0615","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0620","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1756-185X.13060","article-title":"Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais","volume":"20","author":"Foocharoen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0625","first-page":"2055","article-title":"Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse","volume":"23","author":"Amigues","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0630","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2249.1999.00961.x","article-title":"Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis","volume":"117","author":"Ihn","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0635","first-page":"199","article-title":"Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury","volume":"23","author":"Assous","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0640","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semarthrit.2016.10.004","article-title":"Clinical relevance of antiphospholipid antibodies in systemic sclerosis: A systematic review and meta-analysis","volume":"46","author":"Merashli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0645","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/art.24684","article-title":"Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients","volume":"60","author":"Boin","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0650","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/art.24364","article-title":"Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology","volume":"60","author":"Dragun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0655","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0660","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0665","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0670","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0675","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0680","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1053\/gast.2002.36057","article-title":"Antibody-mediated gastrointestinal dysmotility in scleroderma","volume":"123","author":"Goldblatt","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0685","doi-asserted-by":"crossref","first-page":"G1206","DOI":"10.1152\/ajpgi.00286.2009","article-title":"Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells","volume":"297","author":"Singh","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0690","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0695","first-page":"992","article-title":"More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies. Are they useful tools for prognostic use in systemic sclerosis?","volume":"26","author":"Riccieri","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0700","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1002\/art.21952","article-title":"Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies","volume":"54","author":"Ahmed","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0705","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1172\/JCI107827","article-title":"Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast","volume":"54","author":"LeRoy","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2018.04.008_bb0710","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0889-857X(05)70294-5","article-title":"Pathogenesis of scleroderma","volume":"22","author":"Jimenez","year":"1996","journal-title":"Collagen Rheum Dis Clin North Am"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18300671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18300671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T22:58:30Z","timestamp":1720220310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X18300671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0738081X18300671"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.008","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}